
Please try another search
By Sam Boughedda
On Friday, the U.S. Food and Drug Administration approved lecanemab, the Alzheimer's drug developed by Eisai Co (OTC:ESALY) and Biogen (NASDAQ:BIIB) for patients in the earliest stages of the disease.
The drug, which will be sold under the name Leqembi, is the second of a new category of medications approved for Alzheimer's disease that aims to slow its advancement.
In a release by Eisai, it was revealed that the price of the drug will be $26,500 in the U.S.
Following the news, Biogen shares jumped 3.5%.
Leqembi was approved under the Accelerated Approval pathway, which allows the FDA to approve drugs for serious conditions when there is an unmet medical need, and the drug is shown to have an effect. The drug is intended for use in patients with mild cognitive impairment or mild dementia stage of the disease.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.